Germany's Bayer Looks To Chinese Investments Before Entering Market
This article was originally published in PharmAsia News
Germany's Bayer MaterialScience AG plans greater investments in China as part of an effort to present itself to the world as a leader in producing polycarbonates
You may also be interested in...
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma